RadioMedix and Curium Detectnet (copper Cu 64 dotatate injection) Receives US FDA’s Approval for Positive Neuroendocrine Tumors (NETs)

 RadioMedix and Curium Detectnet (copper Cu 64 dotatate injection) Receives US FDA’s Approval for Positive Neuroendocrine Tumors (NETs)

RadioMedix and Curium Detectnet (copper Cu 64 dotatate injection) Receives US FDA’s Approval for Positive Neuroendocrine Tumors (NETs)

Shots:

  • The approval is based on P-lll study which involves assessing Detectnet (copper Cu 64 dotatate injection) in Neuroendocrine Tumors (NETs) patients. Curium expects to launch detectnet immediately with doses available through various nuclear pharmacies
  • The P-III results demonstrated that the clinical sensitivity and specificity provide great aid to clinicians to develop an accurate treatment approach for their NET patients. Additionally, 12.7-hrs. half-life allows detectnet to be produced centrally and shipped to sites
  • Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients

    Click here to­ read the full press release/ article | Ref: Globenewswire | Image: Radiomedix.com

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post